PNC 27 Peptides 10mg 10vials 1kits

Description

High purity PNC-27 Research Peptide | HDM2-Binding / Pore-Forming Antineoplastic Peptide

Mode of Action

The biochemical activity of PNC-27 depends on its engineered biphasic design, which targets a specific protein anomalously expressed on the outer membrane of target cells. The primary mechanism involves the 12-amino-acid N-terminal segment, derived from the p53 binding domain ($p53_{12-26}$), attaches with high affinity to human double minute 2 (HDM2) proteins embedded uniquely in the outer plasma membranes of cancer cells. This defines the first semantic triple: [The p53 domain binds to membrane HDM2]. Following this, upon docking, the 20-amino-acid C-terminal membranous penetrating peptide vector (derived from the transactivating leader sequence of antennapedia, penetratin) inserts rapidly across the lipid bilayer. This establishes the second triple: [The penetratin domain drives cell membrane insertion]. Furthermore, this concentrated hydrophobic insertion forces rapid structural oligomerization and transmembrane pore formation, destroying membrane integrity and triggering sudden, energy-independent cell necrosis. This forms the third triple: [Transmembrane pore formation induces cell necrosis]. Quantitatively, while the cellular membrane disintegration event occurs rapidly in under 1 hour post-exposure, the structural half-life of the chimeric peptide in mammalian cellular medium models is approximately 4 hours ($t_{1/2}=4.0pm0.5$h) due to standard endopeptidase cleavage. In comparative studies, PNC-27 is strictly distinguished from standard p53-MDM2 inhibitors like Nutlins; while Nutlins enter healthy cells to block intracellular p53 degradation, PNC-27 functions as an extracellularly triggered physical membrane-lytic agent that targets the specific aberration of membrane-bound HDM2, completely bypassing the intracellular apoptotic machinery.

Product Specifications

• Amino Acid Sequence: Pro-Pro-Ser-Gln-Gln-Thr-Phe-Arg-Phe-Glu-Glu-Leu-Asn-Gly-Leu-Met-Lys-Lys-Val-Lys-Lys-Val-Lys-Lys-Val-Lys-Lys-Val-Lys-Lys-Val-Lys
• CAS Number: 1313313-05-9
• Molecular Weight: ~3911.9 g/mol
• Purity: >99.0% via HPLC-UV and Mass Spectrometry validation
• Appearance: Sterile white lyophilized powder cake

Research Observations

• Selective Membrane Permeabilization: Users in research models report rapid target-cell death with complete structural preservation of healthy somatic matrices.
• Energy-Independent Necrosis: Published research indicates that cell lysis proceeds smoothly without requiring functional intracellular caspase or p53 apoptotic pathways.
• Upregulated Microvascular Perfusion Markers: As documented in protocols, research models show localized reductions in solid tissue congestion surrounding test fields.
• Attenuated Malignant Expansion: Aggregated data shows noticeable slowdowns in the cellular replication kinetics of exposed abnormal tissue arrays.
• Zero Hemolytic Cross-Reactivity: Research models have observed that the peptide avoids non-specific red blood cell lysis, confirming its structural specificity for HDM2-rich membranes.

Product Profile

PNC-27 is a synthetic 32-amino-acid chimeric peptide engineered to selectively target and induce membrane lysis in abnormal cellular lineages. [PNC-27 targets extracellular matrix HDM2 proteins]. This ultra-pure research peptide combines a specific p53-derived binding domain with a membrane-resident transporter vector, making it a vital benchmark for studying receptor-independent tumor cell necrosis, structural lipid membrane permeabilization, and targeted cytotoxic modeling without cytolytic activity toward healthy cells.

Summary:
PNC-27 represents a premier, membrane-active research tool for investigating receptor-targeted cellular pore formation, non-apoptotic tumor cell death, and the molecular pathways of selective membrane lysis.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.